Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASR | P41180 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL128115 | 0.99 | CASR (0.98) | CASR | |
| SCHEMBL128927 | 0.91 | CASR (0.83) | CASR | |
| Hydrochloric Acid SCHEMBL125565 | 0.90 | CASR (0.82) | CASR | |
| SCHEMBL170257 | 0.90 | CASR (0.85) | CASR | |
| SCHEMBL172222 | 0.90 | CASR (1.00) | CASR | |
| SCHEMBL127686 | 0.90 | CASR (0.81) | CASR | |
| SCHEMBL127866 | 0.89 | CASR (0.89) | CASR | |
| Hydrochloric Acid SCHEMBL128247 | 0.89 | CASR (0.98) | CASR | |
| Hydrochloric Acid SCHEMBL128875 | 0.88 | CASR (0.87) | CASR | |
| SCHEMBL125231 | 0.88 | CASR (0.90) | CASR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110144102-A1 | CALCIMIMETIC COMPOUND FOR USE IN THE TREATMENT OF EPITHELIAL INJURY | AMGEN INC. | 2011-06-16 | — | — | US | claimed |
| EP-2139462-A2 | CALCIMIMETIC COMPOUNDS FOR USE IN THE TREATMENT OF BOWEL DISORDERS | Amgen Inc. (US) | 2010-01-06 | — | — | EP | claimed |
| EP-2037736-A1 | METHODS FOR TREATING CYSTIC KIDNEY DISEASES | Indiana University Research and Technology Corporation (US) | 2009-03-25 | — | — | EP | claimed |
| US-20090018135-A1 | Methods of treating bowel disorders | AMGEN INC. (US) | 2009-01-15 | — | — | US | claimed |
| EP-2010150-A2 | STABLE EMULSION FORMULATIONS | Amgen Inc. (US) | 2009-01-07 | — | — | EP | claimed |
| WO-2008121386-A2 | CALCIMIMETIC COMPOUNDS FOR USE IN THE TREATMENT OF BOWEL DISORDERS | AMGEN INC. (US) | 2008-10-09 | — | — | WO | claimed |
| US-20080027052-A1 | METHODS FOR TREATING CYSTIC KIDNEY DISEASE | INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION | 2008-01-31 | — | — | US | claimed |
| WO-2008008650-A1 | METHODS FOR TREATING CYSTIC KIDNEY DISEASES | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2008-01-17 | — | — | WO | claimed |
| WO-2007124465-A2 | STABLE EMULSION FORMULATIONS | AMGEN INC. (US) | 2007-11-01 | — | — | WO | claimed |
| US-20070249520-A1 | STABLE EMULSION FORMULATIONS | AMGEN INC. (US) | 2007-10-25 | — | — | US | claimed |
| US-8779004-B2 | Stable emulsion formulations | AMGEN, INC. (US) | 2014-07-15 | — | — | US | disclosed |
| US-8609655-B2 | Calcimimetic compound for use in the treatment of epithelial injury | AMGEN INC. (US) | 2013-12-17 | — | — | US | disclosed |
| US-20120283255-A1 | UREA DERIVATIVES, METHODS FOR THEIR MANUFACTURE, AND USES THEREFOR | GALAPAGOS SASU (FR) | 2012-11-08 | — | — | US | disclosed |
| US-20120283255-A1 | UREA DERIVATIVES, METHODS FOR THEIR MANUFACTURE, AND USES THEREFOR | GALAPAGOS SASU (FR) | 2012-11-08 | — | — | US | disclosed |
| US-20120232158-A1 | METHODS OF TREATING HYPERACIDIC DISORDERS | YALE UNIVERISTY | 2012-09-13 | — | — | US | disclosed |
| EP-2010150-A2 | STABLE EMULSION FORMULATIONS | Amgen Inc. (US) | 2009-01-07 | — | — | EP | disclosed |
| US-20080027052-A1 | METHODS FOR TREATING CYSTIC KIDNEY DISEASE | INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION | 2008-01-31 | — | — | US | disclosed |
| WO-2008008650-A1 | METHODS FOR TREATING CYSTIC KIDNEY DISEASES | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2008-01-17 | — | — | WO | disclosed |
| WO-2007124465-A2 | STABLE EMULSION FORMULATIONS | AMGEN INC. (US) | 2007-11-01 | — | — | WO | disclosed |
| US-20070249520-A1 | STABLE EMULSION FORMULATIONS | AMGEN INC. (US) | 2007-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120232158-A1 | METHODS OF TREATING HYPERACIDIC DISORDERS | HRH2, GRPR, SLC10A2 | CASR 8/4885 |
| US-20090018135-A1 | Methods of treating bowel disorders | SLC10A2, FABP2, ALPI | CASR 224/4885 |
| US-20080027052-A1 | METHODS FOR TREATING CYSTIC KIDNEY DISEASE | PKD2, PKD1, REN | CASR 14/4885 |
| US-20120283255-A1 | UREA DERIVATIVES, METHODS FOR THEIR MANUFACTURE, AND USES THEREFOR | UTS2R, UGP2, SLC14A1 | CASR 4125/4885 |
| US-20070249520-A1 | STABLE EMULSION FORMULATIONS | CALCR, CALCB, CALCRL | CASR 153/4885 |
| US-20110144102-A1 | CALCIMIMETIC COMPOUND FOR USE IN THE TREATMENT OF EPITHELIAL INJURY | HIF1AN, HIF1A, CASR | CASR 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.